journal article·2024-12

Systemic Administration of Neurotransmitter‐Derived Lipidoids‐PROTACs‐DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy

Baofeng Gong, Weicong Zhang, Wei Cong, Yuankai Gu, Wenbo Ji, Tong Yin, Honglei Zhou, Honggang Hu, Jianhua Zhuang, Yi Luo, Yan Liu, Jie Gao, You Yin

Advanced Healthcare Materials· Volume 13· Issue 32
Publisher page

Abstract

Abstract Alzheimer's disease (AD) poses a significant burden on the economy and healthcare systems worldwide. Although the pathophysiology of AD remains debatable, its progression is strongly correlated with the accumulation of tau aggregates. Therefore, tau clearance from brain lesions can be a promising strategy for AD therapy. To achieve this, the present study combined proteolysis‐targeting chimera (PROTAC), a novel protein‐degradation technique that mediates degradation of target proteins via the ubiquitin‐proteasome system, and a neurotransmitter‐derived lipidoid (NT‐lipidoid) nanoparticle delivery system with high blood‐brain barrier‐penetration activity, to generate a novel nanomedicine named NPD. Peptide 1, a cationic tau‐targeting PROTAC is loaded onto the positively charged nanoparticles using DNA‐intercalation technology. The resulting nanomedicine displayed good encapsulation efficiency, serum stability, drug release profile, and blood‐brain barrier‐penetration capability. Furthermore, NPD potently induced tau clearance in both cultured neuronal cells and the brains of AD mice. Moreover, intravenous injection of NPD led to a significant improvement in the cognitive function of the AD mice, without any remarkable abnormalities, thereby supporting its clinical development. Collectively, the novel nanomedicine developed in this study may serve as an innovative strategy for AD therapy, since it effectively and specifically induces tau protein clearance in brain lesions, which in turn enhances cognition.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Protein Degradation and Inhibitors · Graphene and Nanomaterials Applications · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurology Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University Shanghai 200003 China

School of Pharmacy University College London London WC1N 1AX UK

School of Medicine Shanghai University Shanghai 200444 China

Department of General Surgery First Affiliated Hospital of Nanjing Medical University Nanjing 210029 China

New Drug Discovery and Development Biotheus Inc. Zhuhai 519080 China

Clinical Pharmacy Innovation Institute Shanghai Jiao Tong University of Medicine Shanghai 200240 China

Department of Clinical Pharmacy Xinhua Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200092 China

Changhai Clinical Research Unit Shanghai Changhai Hospital Naval Medical University Shanghai 200433 China

Department of Neurology Shanghai East Hospital School of Medicine Tongji University Shanghai 200120 China

Funding

Natural Science Foundation of Shanghai Municipality

References (71)

Show source-provided references
1. 10.4103/0366-6999.23511210.4103/0366-6999.235112 ↗
2. Alzheimers Dement. 2020
3. 10.1016/j.jalz.2013.12.02410.1016/j.jalz.2013.12.024 ↗
4. 10.3233/JAD-17993510.3233/JAD-179935 ↗
5. 10.1056/NEJMoa121095110.1056/NEJMoa1210951 ↗
6. 10.1056/NEJMoa130483910.1056/NEJMoa1304839 ↗
7. 10.1056/NEJMoa131288910.1056/NEJMoa1312889 ↗
8. 10.1055/s-0039-167858110.1055/s-0039-1678581 ↗
9. 10.1016/S0140-6736(20)32205-410.1016/S0140-6736(20)32205-4 ↗
10. 10.3390/ijms1503467110.3390/ijms15034671 ↗
11. 10.1016/S0140-6736(15)01124-110.1016/S0140-6736(15)01124-1 ↗
12. 10.2174/138955752266622021409282410.2174/1389557522666220214092824 ↗
13. 10.1038/nrd.2016.21110.1038/nrd.2016.211 ↗
14. 10.1002/anie.20130776110.1002/anie.201307761 ↗
15. 10.1016/j.ejmech.2018.01.06310.1016/j.ejmech.2018.01.063 ↗
16. 10.1016/j.chembiol.2016.02.01610.1016/j.chembiol.2016.02.016 ↗
17. 10.1021/acs.chemrev.0c0053210.1021/acs.chemrev.0c00532 ↗
18. 10.1126/science.abb825510.1126/science.abb8255 ↗
19. 10.1002/advs.20220185910.1002/advs.202201859 ↗
20. 10.1126/sciadv.abb442910.1126/sciadv.abb4429 ↗
21. 10.1016/j.biomaterials.2011.09.03510.1016/j.biomaterials.2011.09.035 ↗
22. 10.1016/j.biomaterials.2011.01.03410.1016/j.biomaterials.2011.01.034 ↗
23. 10.1016/j.biomaterials.2009.11.11210.1016/j.biomaterials.2009.11.112 ↗
24. 10.1016/j.biomaterials.2013.08.08810.1016/j.biomaterials.2013.08.088 ↗
25. 10.1016/j.jconrel.2008.07.00610.1016/j.jconrel.2008.07.006 ↗
26. 10.1080/10717544.2021.195472710.1080/10717544.2021.1954727 ↗
27. 10.1038/nbt.333010.1038/nbt.3330 ↗
28. 10.3389/fnins.2022.85812610.3389/fnins.2022.858126 ↗
29. 10.1002/adma.20180136210.1002/adma.201801362 ↗
30. 10.1038/s41421-018-0079-110.1038/s41421-018-0079-1 ↗
31. 10.18632/oncotarget.999610.18632/oncotarget.9996 ↗
32. 10.1021/acsnano.8b0288110.1021/acsnano.8b02881 ↗
33. 10.1002/smll.20230857410.1002/smll.202308574 ↗
34. 10.1002/smll.20140065410.1002/smll.201400654 ↗
35. 10.1016/j.redox.2019.10113310.1016/j.redox.2019.101133 ↗
36. 10.1073/pnas.201722511810.1073/pnas.2017225118 ↗
37. 10.1007/s00401-017-1674-110.1007/s00401-017-1674-1 ↗
38. 10.1038/s41467-020-16984-110.1038/s41467-020-16984-1 ↗
39. 10.1038/nrn.2015.110.1038/nrn.2015.1 ↗
40. 10.4103/1673-5374.19122710.4103/1673-5374.191227 ↗
41. 10.1126/scitranslmed.aba739410.1126/scitranslmed.aba7394 ↗
42. 10.1038/s41398-022-02004-x10.1038/s41398-022-02004-x ↗
43. 10.1186/s12929-019-0524-y10.1186/s12929-019-0524-y ↗
44. 10.1186/s13024-016-0126-z10.1186/s13024-016-0126-z ↗
45. 10.1186/s13024-015-0052-510.1186/s13024-015-0052-5 ↗
46. 10.1016/j.neuron.2010.08.04410.1016/j.neuron.2010.08.044 ↗
47. 10.1038/nrneurol.2016.2410.1038/nrneurol.2016.24 ↗
48. 10.1016/j.cub.2020.04.08710.1016/j.cub.2020.04.087 ↗
49. 10.1093/nsr/nwz12410.1093/nsr/nwz124 ↗
50. 10.1038/s41467-021-23508-y10.1038/s41467-021-23508-y ↗
51. 10.3390/pharmaceutics1402045810.3390/pharmaceutics14020458 ↗
52. Liu R. · Research (Wash D C) · 2022 · 2022
53. 10.1016/j.jconrel.2012.03.02610.1016/j.jconrel.2012.03.026 ↗
54. 10.3390/ijms22201129810.3390/ijms222011298 ↗
55. 10.1021/acs.accounts.0c0032310.1021/acs.accounts.0c00323 ↗
56. 10.1038/nmat244210.1038/nmat2442 ↗
57. 10.1007/s00018-019-03349-110.1007/s00018-019-03349-1 ↗
58. 10.1371/journal.pmed.100225810.1371/journal.pmed.1002258 ↗
59. 10.2967/jnumed.118.21323110.2967/jnumed.118.213231 ↗
60. 10.1038/s41582-018-0013-z10.1038/s41582-018-0013-z ↗
61. 10.1038/s41591-019-0668-z10.1038/s41591-019-0668-z ↗
62. 10.1186/s13045-020-00885-310.1186/s13045-020-00885-3 ↗
63. 10.7150/thno.5568010.7150/thno.55680 ↗
64. 10.1016/j.biomaterials.2018.04.02410.1016/j.biomaterials.2018.04.024 ↗
65. 10.3390/pharmaceutics1312215310.3390/pharmaceutics13122153 ↗
66. 10.1152/physrev.00015.202010.1152/physrev.00015.2020 ↗
67. 10.1186/s13024-020-00391-710.1186/s13024-020-00391-7 ↗
68. 10.3892/br.2016.63010.3892/br.2016.630 ↗
69. 10.1016/j.clinbiochem.2019.04.00110.1016/j.clinbiochem.2019.04.001 ↗
70. 10.1186/s13024-022-00588-y10.1186/s13024-022-00588-y ↗
71. 10.1021/acsnano.7b0762510.1021/acsnano.7b07625 ↗